With immunotherapy research, targeting the PD-1/PD-L1 pathway and combining it with other therapeutic options has resulted in a significant increase in the survival of patients with advanced LC, making immune checkpoint inhibitors (ICIs) the preferred treatment for advanced LC at this time (4, 141, 142). This evidence concerns the gene CD274 and laryngotracheoesophageal cleft.